Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.6% - Time to Sell?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) dropped 4.6% during trading on Tuesday . The company traded as low as $2.16 and last traded at $2.16. Approximately 234,556 shares changed hands during trading, a decline of 78% from the average daily volume of 1,070,384 shares. The stock had previously closed at $2.26.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AUTL shares. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

The business's 50-day moving average price is $2.57 and its 200 day moving average price is $3.48. The firm has a market capitalization of $585.40 million, a price-to-earnings ratio of -1.82 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) earnings per share. As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AUTL. ProShare Advisors LLC acquired a new position in Autolus Therapeutics during the 2nd quarter valued at about $43,000. Millennium Management LLC raised its holdings in Autolus Therapeutics by 113.7% during the second quarter. Millennium Management LLC now owns 813,031 shares of the company's stock worth $2,829,000 after purchasing an additional 432,503 shares in the last quarter. Herbst Group LLC acquired a new stake in Autolus Therapeutics in the third quarter worth approximately $91,000. Exchange Traded Concepts LLC boosted its stake in Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock valued at $152,000 after buying an additional 3,740 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Autolus Therapeutics by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock worth $139,000 after acquiring an additional 14,959 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.